Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.5K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ATF4 coordinates amino acid and nucleotide synthesis with selective protein translation to ensure proper DNA replication timing in leukemia cells.

Nature communications·2026
Same author

A tumor suppressor role of the miR-15b/16-2 cluster in T-cell acute lymphoblastic leukemia.

Blood·2026
Same author

Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Leukemia·2026
Same author

circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR/ABL1-positive leukemias.

Blood·2026
Same author

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial.

Cancers·2026
Same author

NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia.

Leukemia & lymphoma·2025
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Related Experiment Video

Updated: Dec 18, 2025

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
06:29

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

5.8K

Selinexor for advanced hematologic malignancies.

Janek S Walker1, Ramiro Garzon1, Rosa Lapalombella1

  • 1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

Leukemia & Lymphoma
|June 16, 2020
PubMed
Summary
This summary is machine-generated.

Selinexor, a novel oral drug, targets exportin 1 (XPO1) to treat advanced cancers. This first-in-class Selective Inhibitor of Nuclear Export (SINE) shows promise as a life-saving option for patients with limited alternatives.

Keywords:
AMLCLLDLCBLKPT-330SelinexorXPO1

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.4K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.1K

Related Experiment Videos

Last Updated: Dec 18, 2025

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
06:29

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

5.8K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.4K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Exportin 1 (XPO1) is a key nuclear exporter identified as a therapeutic target in hematologic tumors.
  • Selective Inhibitors of Nuclear Export (SINEs) are a class of molecular agents designed to inhibit XPO1 function.
  • Selinexor (XPOVIO™) is the first oral SINE molecule approved for penta-refractory multiple myeloma.

Purpose of the Study:

  • To review clinical evidence for selinexor in treating solid and liquid tumors.
  • To establish a comprehensive profile of selinexor as an anti-cancer therapeutic.
  • To assess selinexor's potential in late-stage and aggressive cancers.

Main Methods:

  • Review of recent clinical studies involving selinexor.
  • Analysis of pre-clinical and clinical tumor models.
  • Evaluation of adverse effect management.

Main Results:

  • Selinexor demonstrates potential as an anti-cancer pharmaceutical.
  • The drug is effective against late-stage and highly aggressive tumors.
  • Adverse effects are well-defined and predictable.

Conclusions:

  • Selinexor represents a promising therapeutic option for cancer patients with limited treatment choices.
  • Effective management of adverse effects supports its use in clinical practice.
  • Selinexor offers a potential life-saving treatment for advanced cancers.